SELLAS Life Sciences Group, Inc.
SLS · XNASCIK 1390478fmd_1Y7PBDE2WED44FY9D53PKCKYA9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 2 | 8 | 1 | 0 | – | – |
| Cost of revenue | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | (1) | (0) | (0) | 0 | 0 | 0 | 0 | 1 | – | – |
| Gross profit | – | – | – | – | 2 | 7 | 1 | 0 | – | – |
| Research and development | 11 | 6 | 9 | 7 | 9 | 16 | 20 | 24 | 19 | 16 |
| Selling, general and administrative | 5 | 15 | 13 | 10 | 10 | 11 | 13 | 14 | 12 | 12 |
| Total operating expenses | 32 | – | – | – | – | – | – | – | – | – |
| Operating income | (16) | (23) | – | (20) | (17) | (25) | (42) | (38) | (32) | (28) |
| Other non-operating income (expense) | 21 | (24) | (29) | (19) | 0 | 4 | 1 | 1 | 1 | 1 |
| Income before taxes | (18) | (24) | (29) | (19) | (17) | (21) | (41) | (37) | (31) | (27) |
| Income tax expense | 0 | 0 | (1) | (0) | (0) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (11) | (24) | (28) | (19) | (17) | (21) | (41) | (37) | (31) | (27) |
| Net income | (18) | (24) | (28) | (19) | (17) | (21) | (41) | (37) | (31) | (27) |
| Net income to common shareholders | (18) | (24) | (41) | (28) | (17) | (21) | – | – | – | – |